In contrast to the use of vaccines as monotherapy, several studies have demonstrated their potential synergy in tumor control when used in combination with both standard therapies and immune checkpoint inhibitors such as Programmed Death-ligand 1 (PD-L1) and CTL Antigen 4 (CTLA-4) [53]. The gene discussed is CTLA4; the disease is neoplasm.